Senior Fund Controller
About the job
- 3–5 years of experience in fund accounting, financial reporting, audit, or a related function within asset management, management companies, or audit firms.
- Strong knowledge of Luxembourg generally accepted accounting principles, International Financial Reporting Standards, and Undertakings for Collective Investment in Transferable Securities/Alternative Investment Fund Managers regulatory frameworks.
- Strong analytical skills and attention to detail.
- Strong Excel and data analysis skills, with proficiency in Microsoft Office applications including Word, PowerPoint, and Outlook.
- Excellent verbal and written communication skills.
- Fluency in English is required.
- Lead the end-to-end audit process for the funds, serving as a primary contact for auditors and administrators and ensuring timely resolution of queries and deliverables.
- Lead the review of annual, semi-annual, and ad hoc financial reporting deliverables, including financial statements, disclosures, and templates prepared by third-party administrators.
- Provide senior technical oversight across Luxembourg generally accepted accounting principles, International Financial Reporting Standards, and Undertakings for Collective Investment in Transferable Securities/Alternative Investment Fund Managers requirements, ensuring accurate, complete, and compliant financial reporting and disclosures.
- Oversee preparation and review of Self-Assessment Questionnaires and Separate Reports, coordinating input across internal teams and auditors.
- Support preparation of board materials, including financial statements, executive summaries, and representation letters, ensuring clear, high-quality, audit-ready documentation.
- Coordinate and review regulatory disclosures, including remuneration reporting, to align with evolving regulatory requirements.
- Maintain and enhance the financial statement review framework and its control and documentation standards.
- Review and oversee calculation and payment of Luxembourg subscription tax (taxe d’abonnement), ensuring accuracy and regulatory compliance.
- Oversee financial reporting and accounting activities of the Luxembourg Management Company for completeness, accuracy, and compliance with applicable standards.
- Independently review and challenge Management Company financial statements, disclosures, and reconciliations.
- Review trial balances, budgets, and financial performance, identify key variances, and escalate issues as appropriate.
- Coordinate inputs for Self-Assessment Questionnaires, Separate Reports, and other governance reporting exercises, liaising with internal teams and external auditors.
- Support the Management Company annual audit and coordinate quarterly and annual filing obligations following board approval and audit completion.
- Contribute to the design and ongoing enhancement of the Management Company control framework.
- Support oversight of fund and Management Company budgets, expense forecasting, and fixed administrative fee monitoring.
- Review expense service-provider reporting, including accruals, variances, and invoice tracking, and ensure appropriate challenge and escalation.
- Contribute to expense modelling and pro forma preparation for new fund launches.
- Lead preparation of board materials, including financial statements, executive summaries, and representation letters, with a focus on clarity, transparency, and accuracy.
- Identify and drive process improvements, including automation and enhanced reporting efficiency.
- Lead or support projects related to regulatory change, business initiatives, and operational enhancements.
- Promote continuous improvement of governance, reporting, and control frameworks.
- Contribute to internal and external audit reviews and track remediation actions.
- Monitor and report key performance indicators.
- Maintain oversight of key processes performed by third-party vendors, ensuring adherence to service-level agreements, contracts, and control standards.
- Complete annual and periodic due diligence questionnaire reviews for delegates and key vendors.
- Conduct annual reviews of service-provider controls reports, such as SOC 1 reports.
- Support the Fund Control function.
- Identify process-enhancement projects and assess their effectiveness and viability in improving the Finance and Accounting Management & Corporate Services function.
- Identify reporting inefficiencies between service providers and the Management Company and collaborate on automated solutions.
- Support firm-wide efforts to assess critical vendor capabilities and business continuity processes.
- Experience with Management Company oversight and regulatory reporting is highly desirable.
- A professional qualification such as ACCA/ACA or equivalent is preferred; relevant experience will also be considered.
About the company
Wellington Management is a global investment management firm that offers equity, fixed income, multi-asset, and alternative investments to both institutional clients (such as pension funds, endowments, foundations, and insurers) and individual investors. It manages assets on behalf of clients, earning fees based on assets under management (AUM) and on investment performance. The firm relies on deep research capabilities and market insights to tailor investment strategies that meet client needs, and it integrates environmental, social, and governance (ESG) factors into its process. What sets Wellington Management apart is its broad suite of investment options combined with a commitment to ESG integration and a client-tailored approach, supported by a culture that emphasizes diversity and inclusion. The company’s goal is to help clients achieve their investment objectives by delivering disciplined, research-driven strategies and sustainable investing over the long term.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
$66.1B
Headquarters
Boston, Massachusetts
Founded
1933
Get referred to Wellington Management
See people who can refer or advise you
Simplify's Take
What believers are saying
- Hartford Funds acquisition closes in first quarter 2027, adding wealth distribution.
- The new Wellington-Vanguard-Blackstone solutions expand access to public-private portfolios.
- Wellington’s venture, biotech, climate, and CLO launches broaden fee-bearing alternatives.
What critics are saying
- Hartford Funds integration carries execution risk until regulators approve the Q1 2027 close.
- Steve Klar’s retirement in June 2026 exposes client-platform succession risk.
- Passive giants and private-credit rivals compress Wellington’s fees and threaten AUM growth.
What makes Wellington Management unique
- Wellington blends public and private markets through alliances with Vanguard and Blackstone.
- Its $1.35 trillion platform spans 60 countries and over 2,500 institutional clients.
- Matt Witheiler’s Forbes Midas List streak validates Wellington’s late-stage growth investing credibility.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Comprehensive health coverage
Work-life balance
Financial future
Development
Company News
Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing orally bioavailable, small molecule therapies for musculoskeletal diseases, toda...
Alaunos Therapeutics has agreed to raise about $349.95 million through a private placement of stock. It signed a Securities Purchase Agreement to sell 687,789 shares of common stock at $1.4357 per share and 243,063 shares of Series C preferred stock at $1,435.70 per share. The common stock brings in about $987,459, and the preferred stock about $348.97 million. The deal is expected to close on October 14, 2026, subject to customary closing conditions. Fairmount led the placement of Series C non-voting convertible preferred stock. Venrock Healthcare Capital Partners, T. Rowe Price Investment Management, Wellington Management, Janus Henderson Investors, Access Biotechnology, BB Biotech, Perceptive Advisors, Sirenia Capital Management, ADAR1 Capital Management and other firms took part.
We just closed an employee tender offer which values ElevenLabs at $22BN, up 2x from our Series D in February. The tender was led by Wellington and T. Rowe Price, and the growth is driven by demand from enterprises to deploy ElevenAgents across sales, support, and operations. In 2022, we raised our first round at a $9 million valuation, which we announced alongside Eleven v1, our first Text to Speech model, and the first model to generate human-level speech. Four years later, as we reach our new valuation, we just released two new state-of-the-art Text to Speech models. Eleven v4 and v4 Turbo are our fastest and most emotive models yet, and are leading independent benchmarks. Alongside models, we have built a full interaction platform for AI. It allows organizations to deploy conversational agents, connected to their knowledge and systems, that interact naturally in any industry, geography, or context. This shift is driving much of our growth, with enterprise now accounting for 55% of our revenue, as businesses adopt ElevenAgents to support their customers and employees. Our technology is now used in daily operations at five of the world’s ten largest tech companies, five of the ten largest insurers, and four of the ten largest telecoms. The round was co-led by Wellington Management and T. Rowe Price, along with participation from Goldman Sachs, GIC, Ontario Teachers' Pension Plan, EQT Group, Sapphire Ventures, and BDT & MSD Partners. And grateful for ongoing support from existing investors including Andreessen Horowitz, Alkeon Capital, The D. E. Shaw Group, Disruptive, Evantic Capital, ICONIQ, and Lightspeed. Most of all, this round is for the team that built the last four years. We're just getting started! | 89 comments on LinkedIn
Immix Biopharma has priced an underwritten public offering of 11,363,637 shares of common stock at $11.00 per share, expecting gross proceeds of $125 million before deducting underwriting discounts and expenses. The offering is expected to close on or about 30 September 2026. The company intends to use the net proceeds to fund development of NXC-201, working capital, and general corporate purposes. NXC-201 is a CAR-T cell therapy being evaluated for relapsed/refractory AL Amyloidosis and has received Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy designation from the US FDA. J.P. Morgan is acting as sole book-running manager. The offering included participation from institutional investors including Eventide Asset Management, Janus Henderson Investors, Ridgeback Capital Investments, and Wellington Management.
Temporal has raised $550 million in Series E funding at a $12.55 billion valuation, led by Lightspeed Venture Partners. Co-leads include Wellington Management, Growth Equity at Goldman Sachs Alternatives, and Tiger Global. The open-source platform, which powers AI applications, has seen significant growth in 2026. Its annualised revenue run rate recently surpassed $250 million, growing more than 200% year-over-year. Net dollar retention has exceeded 200% since February. Temporal Cloud processed 1.9 trillion actions in August, up more than 350% year-over-year. Open-source installs surpassed 43 million in August, up 134% since January 2026. The company now has more than 4,300 paying customers, including OpenAI, Snap, NVIDIA, Netflix, and JPMorgan Chase. Temporal provides infrastructure for reliable execution of critical applications, from payments to autonomous AI agents.